Invesco Nasdaq Biotechnology ETF is a ETF series of Invesco Exchange-Traded Fund Trust II (series S000072469). Net assets $67.4M as of 2026-05-31. Index fund.
Showing 15 of 200 holdings by value.
| Holding | Ticker | Value | % of fund |
|---|---|---|---|
| Invesco Private Prime Fund | — | $9.6M | 1420.42% |
| Gilead Sciences, Inc. | — | $5.0M | 739.04% |
| Vertex Pharmaceuticals Inc. | — | $5.0M | 737.60% |
| Amgen Inc. | — | $4.8M | 710.49% |
| Invesco Private Government Fund | — | $3.7M | 547.86% |
| Regeneron Pharmaceuticals, Inc. | — | $3.4M | 508.26% |
| Alnylam Pharmaceuticals, Inc. | — | $2.1M | 318.68% |
| Revolution Medicines, Inc. | — | $1.7M | 248.33% |
| Biogen Inc. | — | $1.5M | 228.89% |
| Illumina, Inc. | — | $1.3M | 198.27% |
| United Therapeutics Corp. | — | $1.3M | 194.22% |
| Royalty Pharma PLC | — | $1.3M | 190.09% |
| argenx SE | — | $1.3M | 188.73% |
| Insmed Inc. | — | $1.2M | 183.37% |
| Roivant Sciences Ltd. | — | $1.2M | 170.80% |
| Report date | Net assets |
|---|---|
| 2026-05-31 | $67.4M |
| 2026-02-28 | $75.7M |
| 2025-11-30 | $59.5M |
| 2025-08-31 | $35.8M |
| 2025-05-31 | $35.7M |
| 2025-02-28 | $39.9M |
| 2024-11-30 | $41.1M |
| 2024-08-31 | $38.4M |